3rd ARV agent

DRUG3 trials

Sponsors

Gilead Sciences

Conditions

HIV-1HIV-1 InfectionHIV-1-infection

Phase 2

Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen

CompletedNCT02285114

Gilead SciencesHIV-1

Start: 2015-01-20End: 2024-12-11Updated: 2025-06-27

Phase 3

Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC

CompletedNCT02469246

Gilead SciencesHIV-1 Infection

Start: 2015-06-29End: 2019-03-13Updated: 2019-10-25

Phase 4

A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

RecruitingNCT06337032

Gilead SciencesHIV-1-infection

Start: 2024-08-27End: 2034-03-01Target: 350Updated: 2026-03-16

Related Papers

Longitudinal Evaluation of Bone Safety in Children and Adolescents With HIV-1 Starting Tenofovir Alafenamide-Containing Antiretroviral Therapy

Journal of the Pediatric Infectious Diseases Society2025-07-01

Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial.

2018-02-2016 citations